Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder
University of Utah
20 participants
Jul 15, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD). People with RBD will be enrolled in the study along with their family members (a partner or other family member residing in the same home). All participants will receive the treatment via videoconference and will complete 2 assessments. Participants with RBD will attend 7 sessions, and their family members will attend 2 of those sessions with them.
Eligibility
Inclusion Criteria12
- Diagnosis of isolated RBD or RBD secondary to neurodegenerative disease
- Age 18 or older
- Speak, read, and write English
- Live in the United States
- Nightmare frequency ≥3 times per week
- Disturbing Dream and Nightmare Severity Index score indicative of nightmare disorder
- Sleep, neurological, and psychiatric medications stable for at least 1 month and willing to keep medications stable through the course of the study
- Live with a family member who is willing to participate in the study
- Live with a family member who meets all of the above criteria
- Age 18 or older
- Speak, read, and write English
- Live in the United States
Exclusion Criteria6
- Possible dementia
- Narcolepsy
- Posttraumatic stress disorder
- Previous behavioral treatment for nightmares
- Currently engaged in sleep- or trauma-focused psychotherapy
- Taking a medication that could cause RBD, if the medication was started prior to onset of RBD symptoms
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. Family members will attend 2 of the 7 treatment sessions. During the sessions, participants will learn techniques for managing and changing nightmares.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06441864